AiCuris Announces Expansion of its Collaboration with Lysando with a Focus on Diabetic Foot Infections

AiCuris Anti-infective Cures AG, a leading company in the discovery and development of drugs against infectious diseases, and the biotechnology company Lysando AG with its Regensburg-based subsidiary Lysando GmbH, today announced the expansion of their existing long-term collaboration for the development and optimization of Artilysin(R)-based drug candidates for the topical treatment of infected, chronic wounds such as diabetic foot infections.

AiCuris and Lysando joined forces in 2019 to drive the fight against antimicrobial resistance, with innovative approaches based on Lysando’s Artilysin(R) technology platform, a new class of phage-lysine derived artificial designer molecules with a novel mode of action and the potential to replace conventional antibiotics. Under the terms of the agreement … read more

Newsletter Signup

Subscribe to our weekly newsletter below for an update of everything from the week